TP53 is one of the most commonly mutated genes in cancer. In breast cancer, it is mutated in about 40% of primary clinical tumors and is associated with poor survival. The mammotrophic hormone, prolactin (PRL), and/or its receptor are also expressed in many breast cancers, and accumulating epidemiologic data link PRL to breast cancer development and progression. Like TP53 mutations, evidence for PRL activity is evident across several molecular cancer subtypes, and elevated PRL expression and loss of p53 have been observed in some of the same clinical tumors. In order to examine the interaction of these factors, we used genetically modified mouse models of mammary-specific p53 loss and local overexpression of PRL. We demonstrated that mammary PRL decreased the latency of tumors in the absence of p53, and increased the proportion of triple-negative claudin-low carcinomas, which display similarities to human clinical metaplastic carcinomas. Moreover, PRL/p53 À / À carcinomas displayed higher rates of proliferation and more aggressive behavior. Transcripts associated with cell cycle progression, invasion and stromal reactivity were differentially expressed in carcinomas that developed in the presence of elevated PRL. PRL/p53
INTRODUCTION
TP53 is mutated in 440% of breast cancers of multiple subtypes, and its mutation is associated with poor outcomes. 1, 2 Mouse models have permitted study of the consequences of loss of this powerful tumor suppressor on mammary pathology. 3, 4 Transplantation of p53 À / À mammary epithelium into wild-type recipients leads to stochastic development of carcinomas that display a range of histological and molecular subtypes, modeling the human disease and facilitating study of tumorigenesis in this context. 5, 6 The interaction of mammotropic hormones with pathology induced by dysfunctional p53 has been of particular interest. Although only a minority of the tumors that develop from p53 À / À transplanted cells express estrogen receptor a, 6 prolonged postpubertal supplementation with estrogen and/or progesterone reduces tumor latency. 7 Consistently, treatment with the anti-estrogen, tamoxifen, markedly reduces tumor incidence. 8 However, deletion of the progesterone receptor in the transplanted cells only partially reduces tumor number. 7 The reduction in circulating prolactin (PRL) levels following tamoxifen treatment 8 suggests that this hormone may also contribute to tumorigenesis in the absence of p53.
PRL is a critical player in the development and differentiation of the mammary gland. 9 Epidemiologic evidence also supports a role for PRL in breast cancer. Elevated circulating PRL is linked to the risk of particularly estrogen receptor positive breast cancer. 10 Moreover, locally synthesized PRL further increases exposure of breast tissue in women. [11] [12] [13] [14] [15] [16] Circulating PRL and tumor PRL expression have been associated with metastasis and reduced survival in several studies. [17] [18] [19] [20] In addition, PRL receptor transcripts are elevated in many tumors, compared with adjacent normal tissue, and PRL receptor protein can be stabilized by oncogenic pathways. [21] [22] [23] Interestingly, elevated PRL expression and loss of p53 have been observed in some of the same tumors. 2, 19 However, the mechanisms whereby PRL interacts with other oncogenic factors, including loss of p53, to promote breast cancer are not well understood.
In order to experimentally examine the actions of PRL in mammary pathogenesis, we have developed a transgenic mouse model that expresses PRL in mammary epithelium (neu-related lipocalin (NRL)-PRL), mimicking the local expression of PRL observed in women. 24 In this model, local PRL exposure is elevated without altering circulating PRL or estrous cycling, permitting study of PRL actions without secondary effects on ovarian hormones. Nulliparous NRL-PRL females develop diverse aggressive carcinomas, including many adenocarcinomas with molecular characteristics of the luminal tumor subtype of clinical breast cancer, as well as a small subset of spindle cell carcinomas. 25 Although some of these tumors display phosphorylation of the classical PRL-induced signaling mediator, STAT5, others exhibit high levels of activating protein-1 (AP-1) proteins, which are induced by mitogen-activated protein kinases. 25 This murine model has elucidated the ability of PRL to cooperate with other important players in breast cancer, including growth factors and estrogen. 26, 27 Here we have examined the interplay of PRL and the absence of p53 in mammary pathology, by crossing NRL-PRL mice with p53 null mice in the FVB/N genetic background, and transplanting the genetically modified mammary cells into syngeneic wild-type recipients. Our studies demonstrate that PRL potently promotes the development of aggressive claudin-low carcinomas, associated with selectively altered expression of AP-1 proteins, including higher levels of c-Jun and FosL1.
RESULTS AND DISCUSSION

PRL accelerates tumorigenesis in the context of p53
À / À and shifts the spectrum of tumor histotypes toward triple-negative claudinlow carcinomas Nullizygous p53 mice on the FVB/N genetic background developed multiple tumors (chiefly hemangiosarcomas and lymphomas) as young adults and often did not live beyond 3 months of age (data not shown). 28 Therefore, to examine interactions between p53 status and PRL in mammary tumorigenesis in vivo, we transplanted genetically modified mammary tissue from young adult females to epithelium-free fat pads of wild-type 3-week-old syngeneic females, as reported to study mammary p53 mutations in BALB/c mice. 5 Donor glands of p53 À / À females exhibited normal morphology (Supplementary Figures 1a, e and c, g), as reported in BALB/c mice, 5 and glands expressing the PRL transgene (NRL-PRL) displayed ductal dilation, alveolar development and focal hyperplasias (Supplementary Figures 1b  and e) , as previously described. 24 However, glands which contained cells with elevated PRL combined with p53 loss (NRL-PRL/ p53 À / À ; PRL/p53 À / À ) showed markedly irregular ductal epithelium in addition to these other abnormalities, even at this young age (Supplementary Figures 1d and h) .
Nulliparous nontransgenic recipients bearing transplanted PRL/p53 À / À mammary cells developed carcinomas more rapidly than p53
À / À cells without PRL (Po0.05; Figure 1a and Table 1 ). In contrast, transplanted cells from wild-type and NRL-PRL donors did not develop tumors by 1 year of age, consistent with the long latency of mammary carcinomas in NRL-PRL females. 24, 25 In addition, transgenic PRL significantly shifted the spectrum of tumor histotypes that developed from p53 À / À transplants. FVB/N p53 À / À donor cells developed carcinomas with diverse histotypes (Table 1 , Figures 1b and 2a-c) , as reported for the BALB/c strain. 6 However, nearly all of the tumors that developed from PRL/p53 À / À carcinomas did not express immunologically detectable estrogen receptor a, progesterone receptor, or ErbB2 (human epidermal growth factor receptor 2) (Supplementary Figure 2b) , establishing their resemblance to clinical triple-negative metaplastic carcinomas. In light of the ability of PRL to induce changes in collagen alignment in three-dimensional cultures of breast cancer cells, 29 we examined collagen after staining with picrosirius red. As shown in Figures 2g and h, many of the carcinomas that developed from PRL/p53
À / À cells contained straight, directionally oriented collagen fibers, particularly near the tumor margins, which indicate a more aggressive tumor, 30 compared with the wavy fibers observed in the spindle cell carcinomas that developed from p53 À / À cells.
To further characterize these tumors, we examined levels of transcripts for markers that distinguish breast cancer subtypes. 6 All of the spindle cell carcinomas examined contained very low levels of Cldn 3 and Cldn7 mRNA, in marked contrast to wild-type FVB/N mammary epithelial cells and adenocarcinomas induced by the PRL transgene in the context of wild-type p53 (Figures 1c and d, Po0.0001). Furthermore, these tumors exhibited the transcript signature of the epithelial-to-mesenchymal transition (EMT). 31 Together with the cytokeratin staining, these data confirm that the carcinomas of this histotype that developed from both p53 À / À and PRL/p53 À / À transplanted cells were 'claudin-low' (Figure 1e ). 6, 32, 33 The triple-negative claudin-low subtype of breast cancer comprises about 7-14% of primary clinical breast cancers, and has a worse prognosis than luminal A tumors. 2, 33 This subtype exhibits some resistance to anthracycline/taxane-based chemotherapy, 33 and residual tumors after neoadjuvant chemotherapy or anti-estrogen treatment are enriched in its transcript signature. 33, 34 Clinical claudin-low tumors express high levels of markers for mammary stem cells, 33, 35 and examination of experimental p53
À / À tumors in BALB/c mice demonstrated enrichment in tumor initiating cells. 6 However, the factors that lead to the development and progression of these tumors are not known. Of particular interest in light of the dramatic increase in the proportion of these tumors that developed with PRL exposure in this study, PRL was elevated in 37% of claudin-low tumors in a clinical study, although the sample size was small. 2 Transgenic PRL increases tumor growth and aggression Although the claudin-low carcinomas that developed from both p53 À / À and PRL/p53 À / À cells were locally invasive, the PRL/ p53 À / À tumors were more aggressive. Although all of the tumors from p53 À / À transplants remained confined to the mammary fat pad, 32% of the PRL/p53 À / À carcinomas invaded into the peritoneal cavity (Table 1) . Consistently, carcinomas that developed in the context of locally elevated PRL were significantly larger at end stage, despite the decreased latency (Figure 3a , Po0.05). Moreover, the rate of proliferation of these tumors was significantly higher (Po0.01, Figure 3b ). In order to evaluate potential mechanisms of the increased proliferation, we examined levels of mRNA for multiple cell cycle regulators in claudin-low carcinomas that developed in both genotypes. Interestingly, we identified no differences in transcript levels of cyclins (listed in Supplementary Table 1), but those for two regulators, p16  Ink4a and  p19 Arf , were significantly reduced in PRL/p53 À / À compared with p53 À / À carcinomas ( Figure 3c ). Both p16
Ink4a and p19 Arf are encoded by the Cdkn2a locus. As tumor suppressors, they are disabled in many cancers. 36 Despite the overlap in their genomic organization, these genes have distinct promoters and have different roles to cooperatively regulate the cell cycle and integrate cellular stresses and outcomes. p16
Ink4a represses the activity of CDK4/6 cyclin complexes, and p19
Arf acts in part by blocking degradation of p53 mediated by MDM2, inducing cell cycle arrest or apoptosis. The cooperation of p16
Ink4a and p53 deficiencies in tumorigenesis is well recognized. 37 Interestingly, the BALB/c strain, which has been used extensively to model p53 in mammary tumorigenesis, has a mutated allele of Cdkn2a that impairs the activity of p16 Ink4a . 38 This genetic variation may have obscured a role for PRL on p53-initiated mammary tumorigenesis in this strain. 7, 8 In combination with the ability of PRL to post-transcriptionally stabilize other cell cycle regulators, 39, 40 these findings further illuminate the mechanisms whereby PRL increases mammary cell proliferation. 24, [41] [42] [43] To determine effects on enzyme expression that might impact the observed invasiveness, we examined mRNA for the matrix metalloproteinases (MMPs) À 2, and À 9, which have been associated with tumor invasion and metastases. 44, 45 As shown in Figure 3d , Mmp9, but not Mmp2, mRNA was significantly elevated in PRL/p53 À / À carcinomas. Moreover, transcripts for cathepsin L, another protease important in matrix degradation and invasion in breast cancer, 46 were also elevated in tumors of this genotype.
In light of the ability of PRL to increase transcripts for type I collagen 47 (Rugowski, unpublished observations) and the marked differences in the appearance of collagen fibers in PRL/p53 À / À , compared with p53 À / À spindle cell carcinomas (Figures 2g and   h ), we examined type I collagen mRNAs in these tumors. As shown in Figure 3e , levels of Col1a1, but not Col1a2, mRNA tended to be higher in PRL/p53 À / À carcinomas than p53 À / À carcinomas (P ¼ 0.08, one-tailed Student's t-test). Transcripts for the pro-angiogenic ligand, Vegfa, also tended to be higher (P ¼ 0.086, one-tailed Student's t-test).
Together, these data indicate that PRL modulates expression of genes, which are likely to contribute to the more aggressive phenotype of the claudin-low carcinomas that develop from PRL/ p53 À / À , compared with p53 À / À cells. Figure 1 . PRL decreases the latency of mammary tumors that develop in the absence of p53 and increases the proportion of claudin-low spindle cell carcinomas. NRL-PRL mice (line 1647-13, TgN(Nrl-Prl)23EPS), were generated in the FVB/N strain as described. 24 C57BL/6 mice carrying a deletion for p53 75 were backcrossed 410 generations into the FVB/N genetic background. 76 Mammary fragments from 10-to 13-week-old donors of the genotypes of interest were transplanted to mammary fat pads of 3-week-old wild-type FVB/N mice, which had been cleared of endogenous epithelium as described 77 (5-9 recipients per donor). Nulliparous recipients were examined weekly for tumors until one year of age. À / À donor cells; right, spindle cell carcinoma from PRL/p53 À / À donor cells. Levels of these transcripts in tumors that developed in these genotypes were not significantly different.
PRL/p53
À / À carcinomas express higher levels of AP-1 components associated with aggression PRL/p53 À / À carcinomas exhibited uniformly very low levels of transcripts for two well-characterized mediators of PRL's physiologic actions in the mammary gland, Elf5 and Stat5 48, 49 (data not shown), in contrast to their variable levels in PRL-induced adenocarcinomas. 25 Indeed, these mediators are not associated with the aggressive phenotype of claudin-low tumors, such as those observed in our studies: clinically, activated Stat5 is associated with better differentiated tumors and therapeutic responses, 50, 51 and experimentally, Elf5 inhibits the EMT. 52 Instead, the PRL/p53
À / À carcinomas in this study displayed altered levels of AP-1 components, compared with p53 À / À carcinomas. AP-1 complexes, composed of homo-or hetero-dimers of AP-1 proteins, transcriptionally regulate many key genes controlling proliferation, the EMT and invasion, and are often deregulated in cancers (for reviews, see refs [53] [54] [55] [56] [57] [58] . As shown in Figure 4a , PRL/p53 À / À carcinomas contained significantly higher levels of mRNA for c-Jun and FosL than p53 À / À alone (Po0.05). In contrast, transcripts for c-Fos trended lower (P ¼ 0.16, two-tailed Student's t-test), whereas those for JunB, as well as JunD (data not shown) were similar in tumors of both genotypes. Analysis of protein levels of these components in the carcinomas demonstrated similarly significant patterns (Figure 4b) .
The AP-1 family is dysregulated in 10-15% of breast cancers.
2,59
The activity of AP-1 enhancers is controlled by not only the levels of these complexes, but also the composition of the AP-1 dimers as well as promoter context. 54, 56 c-Jun and FosL1, both elevated in PRL/p53
À / À compared with p53 À / À carcinomas, are associated with poor outcomes in breast cancer in clinical studies. [60] [61] [62] [63] [64] In contrast, other AP-1 proteins, such as c-Fos, which was reduced in our studies in the presence of PRL, are associated with better outcomes.
PRL initiates activation of many mitogen-activated protein kinases, which increase the synthesis and phosphorylation of AP-1 components, 65 and AP-1 proteins are elevated in a subset of PRLinduced mammary carcinomas that develop in NRL-PRL females. 25 The ability of PRL to activate these pathways in vitro is inversely related to its ability to activate Stat5, 66 which also is reflected in PRL-induced carcinomas in mouse models. 25 Although a role for AP-1 signals in hormone-driven postnatal mammary development has been established, 67 a link to physiological actions of PRL action are unclear. Among the genes regulated by AP-1 complexes are those encoding p16
Ink4a and p19
Arf , 68,69 MMP-9 and cathepsin L, 39 Vegfa 70 and type I collagen, 71 as well as those regulating the EMT. 54 Although the transcript profiles of p53
claudin-low carcinomas resemble mammary stem cells, 33, 35 the cells that give rise to these tumors are poorly understood. PRL may be expanding an epithelial sub-population that is the origin of these tumors, promoting progression of early lesions, and/or initiating paracrine signals, which promote this cancer subtype. The secreted transgenic PRL in this model raises local concentrations within the mammary compartment, where it is available to act on any target cells, modeling that in women. Some evidence suggests that PRL can act on a luminal epithelial sub-population, increasing RANKL, which acts on cells with surface markers enriched for mammary stem cells. 72 However, the mammary target cells of PRL are poorly understood. In addition to epithelial cells, stromal cells also contain PRL receptor in rodent models. 73, 74 Ongoing studies to identify the target cells and consequences of PRL action will illuminate the direct and indirect mechanisms by which PRL contributes to this disease.
Our studies demonstrate that PRL can drive the development of the aggressive claudin-low carcinomas that develop in the genetically unstable environment permitted by the absence of p53. The ability of PRL to promote this breast cancer subtype 
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Arbitrary Units Arbitrary Units demonstrates that PRL can influence a subset of nonluminal breast cancers, which may have been obscured by the relative infrequency of these cancers. Our results provide additional mechanistic insight into the effects of PRL on epithelial proliferation, and demonstrate the potential for PRL to directly contribute to other processes in tumor progression via AP-1-regulated genes, including angiogenesis, matrix remodeling and the EMT. The evidence for PRL-augmented AP-1 activity suggests potential therapeutic and/or preventative strategies for this cancer subtype, which may be targeted alone or in combination with another agent. The preclinical model described here will assist in the development of these approaches. 
